Process and product development in the manufacturing of molecular therapeutics

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 4, 1999, Pages 422-429

  Atkinson, E Morrey ^a   Christensen, Janet Rose ^a  

^a Targeted Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

CLINICAL TRIAL; DEVELOPMENT; GENE TARGETING; GENE THERAPY; HUMAN; MEDICAL RESEARCH; REVIEW; RISK ASSESSMENT;

ANIMALS; AUSTRALIA; CLINICAL TRIALS; CLONING, MOLECULAR; CONSUMER PRODUCT SAFETY; DNA, RECOMBINANT; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; EUROPEAN UNION; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERNET; JAPAN; MICE; OUTSOURCED SERVICES; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0032845129     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Boucher RC: Status of gene therapy for cystic fibrosis lung disease [In process citation]. J Clin Invest (1999) 103(4):441-445.
2. Robbins PD, Ghivizzani SC: Viral vectors for gene therapy. Phamacol Ther (1998) 80(1):35-47.
3. Wagner JA, Gardner P: Toward cystic fibrosis gene therapy. Annu Rev Med (1997) 48:203-216.
4. Wiman KG: New p53-based anti-cancer therapeutic strategies [In process citation]. Med Oncol (1998) 15(4):222-228.
5. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC: Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther(1998) 5(11):1538-1544.
6. Schwartz B, Benoist C, Abdallah B, Rangara R, Hassan A, Scherman D, Demeneix BA: Gene transfer by naked DNA into adult mouse brain. Gene Ther(1996) 3(5):405-411.
7. Yang JP, Huang L: Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Ther (1996) 3(6):542-548.
8. Chu Q, Tousignant JD, Fang S, Jiang C, Chen LH, Cheng SH, Scheute RK, Eastman SJ: Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells [In process citation]. Hum Gene Ther (1999) 10(1):25-36.
9. PDA: Guidance for industry: Guidance for human somatic cell therapy and gene therapy. US Food and Drug Admistration - Center for Biologics Evaluation and Research (1998) www.fda.sou/cder/guidence
10. 21 CFR Parts 45, 40, 58, 300-314, 210, 211, 600-610 (1998) United States Government.
11. The Validation Dictionary, Institute of Validation Technology, Royal Palm Beach, FL, USA.
12. FDA Guidance Document: CMC Content and Format of Investigational New Drug Applications (INDs) for Phases 2 and 3 Studies of Drugs, Including Specified Therapeutic Biotechnology-Derived Products (Issued 12/1997).
13. FDA Guidance Document: Stability Testing of Drug Substances and Drug Products (Issued 6/5/1998).
14. FDA Guidance Document: Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients (Issued 4/17/1998).
15. FDA Guidance Document: ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (Issued 11/1997).
16. FDA Guidance Document: ICH M3: Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (Issued 11/1997).
17. FDA Guidance Document: ICH E8: General Considerations for Clinical Trials (Issued 12/1997).
18. FDA Guidance Document: ICH: Q5A Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin (Issued 9/24/98).
19. FDA Guidance Document: ICH: Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products (7/1996).
20. FDA Guidance Document: ICH: Q5D Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates used for Production of Biotechnological/Biological Products (Issued 9/21/98).
21. Chew N: Reinventing FDA, Part 4: Gene, cell, and tissue therapies. BioPharm (1998) 11(5):44-51.
22. Teramoto S, Bartiett JS, McCarty D, Xiao X, Samulski RJ, Boucher RC: Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors. J Virol (1998) 72(11):8904-8912.
23. Amalfitano A, Begy CR, Chamberlain JS: Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA (1996) 93(8):3352-3356.
24. Clark KR, Voulgaropoulou F, Johnson PR: A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther (1996) 3(12):1124-1132.
25. Fisher KJ, Choi H, Burda J, Chen SJ. Wilson JM: Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology (1996) 217(1):11-22.
26. Atkinson E: Presented at the process development and production issues for viral vectors and vaccines. Williamsburg, VA (1998).
27. Horn NA, Meek JA, Budahazi G, Marquet M: Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials. Hum Gene Ther (1995) 6(5):565-573.
28. Huyghe BG, Liu X, Sutjipto S, Sugarman B, Horn MT, Shepard M, Scandella CJ, Shabram P: Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther (1995) 6:1403-1416.
29. Paul RW, Morris D, Hess BW, Dunn J, Overell RW: Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum Gene Ther (1993) 4(5):609-615.
30. Sambrook J, Fritsch EF, Maniatis T (Ed): Molecular cloning: A laboratory manual. Cold Spring Harbor Press, Plainview, NY (1989).
31. Lyddiatt A, O'Sullivan DA: Biochemical recovery and purification of gene therapy vectors. Curr Opin Biotechnol (1998) 9(2):177-185.
32. Kotani H, Newton PB, Zhang S, Chiang YL, Otto E, Weaver L, Blaese RM, Anderson WF, McGarrity GJ: Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther (1994) 5(1):19-28.
33. Millipore: Introduction to tangential flow filtration: Methods for successful scale-up. Process filtration and chromatography seminars for the biotechnology industry. Millipore Corporation, Bedford, MA.
34. Pungor E, Lehmberg E, Chakel J, Cheng R-J, Nelson J, Parkman M, Traina J, Hancock W, McCarnan M, Murakami P, Nestaas E: Presented at the process development and production issues for viral vectors and vaccines. Williamsburg, VA USA (1998).